vs
Side-by-side financial comparison of CollPlant Biotechnologies Ltd (CLGN) and SMITH & NEPHEW PLC (SNN). Click either name above to swap in a different company.
CollPlant Biotechnologies Ltd is a regenerative medicine company focused on developing and commercializing advanced products using its proprietary plant-derived human collagen technology. Its core offerings cover wound care, soft tissue repair, and aesthetic medicine solutions, targeting key markets across North America, Europe, and Israel, serving healthcare providers in dermatology, orthopedics and cosmetic care segments.
Smith & Nephew plc, also known as Smith+Nephew, is a British multinational medical equipment manufacturing company headquartered in Watford, England. It is an international producer of advanced wound management products, arthroscopy products, trauma and clinical therapy products, and orthopaedic reconstruction products. Its products are sold in over 100 countries. It is listed on the London Stock Exchange and is a constituent of the FTSE 100 Index.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $179.0K | — | ||
| Q2 24 | $249.0K | — | ||
| Q2 23 | $10.2M | — | ||
| Q2 22 | $66.0K | — |
| Q2 25 | $-3.3M | — | ||
| Q2 24 | $-4.2M | — | ||
| Q2 23 | $5.8M | — | ||
| Q2 22 | $-4.3M | — |
| Q2 25 | -3.9% | — | ||
| Q2 24 | -115.3% | — | ||
| Q2 23 | 94.0% | — | ||
| Q2 22 | 34.8% | — |
| Q2 25 | -1775.4% | — | ||
| Q2 24 | -1769.5% | — | ||
| Q2 23 | 55.7% | — | ||
| Q2 22 | -6340.9% | — |
| Q2 25 | -1869.8% | — | ||
| Q2 24 | -1690.8% | — | ||
| Q2 23 | 56.6% | — | ||
| Q2 22 | -6492.4% | — |
| Q2 25 | $0.28 | — | ||
| Q2 24 | $0.37 | — | ||
| Q2 23 | $0.49 | — | ||
| Q2 22 | $-0.39 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
